1f8a › Citations

Structural basis for phosphoserine-proline recognition by group IV WW domains.

Verdecia MA, Bowman ME, Lu KP, Hunter T, Noel JP
Nat Struct Biol 7 639-43 (2000)
Cited: 402 times
EuropePMC logo PMID: 10932246

Abstract

Pin1 contains an N-terminal WW domain and a C-terminal peptidyl-prolyl cis-trans isomerase (PPIase) domain connected by a flexible linker. To address the energetic and structural basis for WW domain recognition of phosphoserine (P.Ser)/phosphothreonine (P. Thr)- proline containing proteins, we report the energetic and structural analysis of a Pin1-phosphopeptide complex. The X-ray crystal structure of Pin1 bound to a doubly phosphorylated peptide (Tyr-P.Ser-Pro-Thr-P.Ser-Pro-Ser) representing a heptad repeat of the RNA polymerase II large subunit's C-terminal domain (CTD), reveals the residues involved in the recognition of a single P.Ser side chain, the rings of two prolines, and the backbone of the CTD peptide. The side chains of neighboring Arg and Ser residues along with a backbone amide contribute to recognition of P.Ser. The lack of widespread conservation of the Arg and Ser residues responsible for P.Ser recognition in the WW domain family suggests that only a subset of WW domains can bind P.Ser-Pro in a similar fashion to that of Pin1.

Reviews - 1f8a mentioned but not cited (7)

  1. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Gareau JR, Lima CD. Nat Rev Mol Cell Biol 11 861-871 (2010)
  2. The Ess1 prolyl isomerase: traffic cop of the RNA polymerase II transcription cycle. Hanes SD. Biochim Biophys Acta 1839 316-333 (2014)
  3. Roles of Prolyl Isomerases in RNA-Mediated Gene Expression. Thapar R. Biomolecules 5 974-999 (2015)
  4. Interaction modules that impart specificity to disordered protein. Cermakova K, Hodges HC. Trends Biochem Sci 48 477-490 (2023)
  5. Orchestrating serine/threonine phosphorylation and elucidating downstream effects by short linear motifs. Kliche J, Ivarsson Y. Biochem J 479 1-22 (2022)
  6. Cross-talk of phosphorylation and prolyl isomerization of the C-terminal domain of RNA Polymerase II. Yogesha SD, Mayfield JE, Zhang Y. Molecules 19 1481-1511 (2014)
  7. What's all the phos about? Insights into the phosphorylation state of the RNA polymerase II C-terminal domain via mass spectrometry. LeBlanc BM, Moreno RY, Escobar EE, Venkat Ramani MK, Brodbelt JS, Zhang Y. RSC Chem Biol 2 1084-1095 (2021)

Articles - 1f8a mentioned but not cited (39)



Reviews citing this publication (91)

  1. Validating survivin as a cancer therapeutic target. Altieri DC. Nat Rev Cancer 3 46-54 (2003)
  2. Cell death by mitotic catastrophe: a molecular definition. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Oncogene 23 2825-2837 (2004)
  3. Chromosomal passengers: conducting cell division. Ruchaud S, Carmena M, Earnshaw WC. Nat Rev Mol Cell Biol 8 798-812 (2007)
  4. Survivin, versatile modulation of cell division and apoptosis in cancer. Altieri DC. Oncogene 22 8581-8589 (2003)
  5. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Lu KP, Zhou XZ. Nat Rev Mol Cell Biol 8 904-916 (2007)
  6. The RNA polymerase II CTD coordinates transcription and RNA processing. Hsin JP, Manley JL. Genes Dev 26 2119-2137 (2012)
  7. Prolyl cis-trans isomerization as a molecular timer. Lu KP, Finn G, Lee TH, Nicholson LK. Nat Chem Biol 3 619-629 (2007)
  8. The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Ingham RJ, Gish G, Pawson T. Oncogene 23 1972-1984 (2004)
  9. Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Bentley DL. Curr Opin Cell Biol 17 251-256 (2005)
  10. Structure and mechanism of the RNA polymerase II transcription machinery. Hahn S. Nat Struct Mol Biol 11 394-403 (2004)
  11. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. Macias MJ, Wiesner S, Sudol M. FEBS Lett 513 30-37 (2002)
  12. Protein factors in pre-mRNA 3'-end processing. Mandel CR, Bai Y, Tong L. Cell Mol Life Sci 65 1099-1122 (2008)
  13. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Altieri DC. Trends Mol Med 7 542-547 (2001)
  14. Cracking the RNA polymerase II CTD code. Egloff S, Murphy S. Trends Genet 24 280-288 (2008)
  15. Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Li SS. Biochem J 390 641-653 (2005)
  16. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Zeke A, Misheva M, Reményi A, Bogoyevitch MA. Microbiol Mol Biol Rev 80 793-835 (2016)
  17. Ubiquitin and membrane protein turnover: from cradle to grave. MacGurn JA, Hsu PC, Emr SD. Annu Rev Biochem 81 231-259 (2012)
  18. Pinning down proline-directed phosphorylation signaling. Lu KP, Liou YC, Zhou XZ. Trends Cell Biol 12 164-172 (2002)
  19. NeW wrinkles for an old domain. Sudol M, Hunter T. Cell 103 1001-1004 (2000)
  20. The structure and function of proline recognition domains. Zarrinpar A, Bhattacharyya RP, Lim WA. Sci STKE 2003 RE8 (2003)
  21. Phosphoserine/threonine-binding domains. Yaffe MB, Elia AE. Curr Opin Cell Biol 13 131-138 (2001)
  22. Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Theillet FX, Binolfi A, Frembgen-Kesner T, Hingorani K, Sarkar M, Kyne C, Li C, Crowley PB, Gierasch L, Pielak GJ, Elcock AH, Gershenson A, Selenko P. Chem Rev 114 6661-6714 (2014)
  23. Chromosomal passengers: the four-dimensional regulation of mitotic events. Vagnarelli P, Earnshaw WC. Chromosoma 113 211-222 (2004)
  24. Survivin study: what is the next wave? Li F. J Cell Physiol 197 8-29 (2003)
  25. Structure of eukaryotic RNA polymerases. Cramer P, Armache KJ, Baumli S, Benkert S, Brueckner F, Buchen C, Damsma GE, Dengl S, Geiger SR, Jasiak AJ, Jawhari A, Jennebach S, Kamenski T, Kettenberger H, Kuhn CD, Lehmann E, Leike K, Sydow JF, Vannini A. Annu Rev Biophys 37 337-352 (2008)
  26. Adaptable hydrogel networks with reversible linkages for tissue engineering. Wang H, Heilshorn SC. Adv Mater 27 3717-3736 (2015)
  27. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Altieri DC. Curr Opin Cell Biol 18 609-615 (2006)
  28. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Wulf G, Finn G, Suizu F, Lu KP. Nat Cell Biol 7 435-441 (2005)
  29. Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Reinhardt HC, Yaffe MB. Nat Rev Mol Cell Biol 14 563-580 (2013)
  30. Insights into programmed cell death through structural biology. Fesik SW. Cell 103 273-282 (2000)
  31. Multisite protein modification and intramolecular signaling. Yang XJ. Oncogene 24 1653-1662 (2005)
  32. Protein Allostery and Conformational Dynamics. Guo J, Zhou HX. Chem Rev 116 6503-6515 (2016)
  33. Apoptosis and non-apoptotic deaths in cancer development and treatment response. de Bruin EC, Medema JP. Cancer Treat Rev 34 737-749 (2008)
  34. Survivin: a promising tumor biomarker. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Cancer Lett 249 49-60 (2007)
  35. Pinning down cell signaling, cancer and Alzheimer's disease. Lu KP. Trends Biochem Sci 29 200-209 (2004)
  36. Recognition of proline-rich motifs by protein-protein-interaction domains. Ball LJ, Kühne R, Schneider-Mergener J, Oschkinat H. Angew Chem Int Ed Engl 44 2852-2869 (2005)
  37. The WW domain: linking cell signalling to the membrane cytoskeleton. Ilsley JL, Sudol M, Winder SJ. Cell Signal 14 183-189 (2002)
  38. RNA polymerase II C-terminal domain: Tethering transcription to transcript and template. Corden JL. Chem Rev 113 8423-8455 (2013)
  39. The case for Survivin as mitotic regulator. Lens SM, Vader G, Medema RH. Curr Opin Cell Biol 18 616-622 (2006)
  40. Molecular evolution of the RNA polymerase II CTD. Chapman RD, Heidemann M, Hintermair C, Eick D. Trends Genet 24 289-296 (2008)
  41. The alphabet of intrinsic disorder: I. Act like a Pro: On the abundance and roles of proline residues in intrinsically disordered proteins. Theillet FX, Kalmar L, Tompa P, Han KH, Selenko P, Dunker AK, Daughdrill GW, Uversky VN. Intrinsically Disord Proteins 1 e24360 (2013)
  42. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Mol Cancer 10 35 (2011)
  43. RNA processing and export. Hocine S, Singer RH, Grünwald D. Cold Spring Harb Perspect Biol 2 a000752 (2010)
  44. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. Altieri DC. J Cell Biochem 92 656-663 (2004)
  45. Pin1 in Alzheimer's disease. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R. J Neurochem 98 1697-1706 (2006)
  46. Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Shaw PE, Saxton J. Int J Biochem Cell Biol 35 1210-1226 (2003)
  47. Understanding IAP function and regulation: a view from Drosophila. Hay BA. Cell Death Differ 7 1045-1056 (2000)
  48. Peptidyl-prolyl isomerases: a new twist to transcription. Shaw PE. EMBO Rep 3 521-526 (2002)
  49. BIRinging chromosomes through cell division--and survivin' the experience. Reed JC, Bischoff JR. Cell 102 545-548 (2000)
  50. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. Chen Y, Wu YR, Yang HY, Li XZ, Jie MM, Hu CJ, Wu YY, Yang SM, Yang YB. Cell Death Dis 9 883 (2018)
  51. Trafficking and cell surface stability of ENaC. Rotin D, Kanelis V, Schild L. Am J Physiol Renal Physiol 281 F391-9 (2001)
  52. The cell cycle as a therapeutic target for Alzheimer's disease. Neve RL, McPhie DL. Pharmacol Ther 111 99-113 (2006)
  53. An overview of apoptosis and the prevention of colorectal cancer. Watson AJ. Crit Rev Oncol Hematol 57 107-121 (2006)
  54. PhosphoSerine/threonine binding domains: you can't pSERious? Yaffe MB, Smerdon SJ. Structure 9 R33-8 (2001)
  55. Prolyl isomerases in gene transcription. Hanes SD. Biochim Biophys Acta 1850 2017-2034 (2015)
  56. The use of in vitro peptide-library screens in the analysis of phosphoserine/threonine-binding domain structure and function. Yaffe MB, Smerdon SJ. Annu Rev Biophys Biomol Struct 33 225-244 (2004)
  57. The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. Huang Z. Chem Biol 9 1059-1072 (2002)
  58. Natural cellular inhibitors of caspases. LeBlanc AC. Prog Neuropsychopharmacol Biol Psychiatry 27 215-229 (2003)
  59. Peptidyl-prolyl cis/trans isomerases and transcription: is there a twist in the tail? Shaw PE. EMBO Rep 8 40-45 (2007)
  60. Targeting HECT-type E3 ligases - insights from catalysis, regulation and inhibitors. Fajner V, Maspero E, Polo S. FEBS Lett 591 2636-2647 (2017)
  61. Protein recognition using synthetic small-molecular binders toward optical protein sensing in vitro and in live cells. Kubota R, Hamachi I. Chem Soc Rev 44 4454-4471 (2015)
  62. The CTD code of RNA polymerase II: a structural view. Jasnovidova O, Stefl R. Wiley Interdiscip Rev RNA 4 1-16 (2013)
  63. Tetraploidy/aneuploidy and stem cells in cancer promotion: The role of chromosome passenger proteins. Nguyen HG, Ravid K. J Cell Physiol 208 12-22 (2006)
  64. Molecular mechanisms of the phospho-dependent prolyl cis/trans isomerase Pin1. Lippens G, Landrieu I, Smet C. FEBS J 274 5211-5222 (2007)
  65. Targeting carcinogenesis: a role for the prolyl isomerase Pin1? Lu KP, Suizu F, Zhou XZ, Finn G, Lam P, Wulf G. Mol Carcinog 45 397-402 (2006)
  66. NAIPs: building an innate immune barrier against bacterial pathogens. NAIPs function as sensors that initiate innate immunity by detection of bacterial proteins in the host cell cytosol. Kofoed EM, Vance RE. Bioessays 34 589-598 (2012)
  67. Peptidyl-prolyl isomerase inhibitors. Wang XJ, Etzkorn FA. Biopolymers 84 125-146 (2006)
  68. Regulation of AU-Rich Element RNA Binding Proteins by Phosphorylation and the Prolyl Isomerase Pin1. Shen ZJ, Malter JS. Biomolecules 5 412-434 (2015)
  69. A tale of chromatin and transcription in 100 structures. Cramer P. Cell 159 985-994 (2014)
  70. The roles of peptidyl-proline isomerases in gene regulation. Dilworth D, Gudavicius G, Leung A, Nelson CJ. Biochem Cell Biol 90 55-69 (2012)
  71. Apoptosis and toxicology--what relevance? Vaux DL. Toxicology 181-182 3-7 (2002)
  72. Gears-In-Motion: The Interplay of WW and PPIase Domains in Pin1. Lee YM, Liou YC. Front Oncol 8 469 (2018)
  73. Lessons from nature: On the molecular recognition elements of the phosphoprotein binding-domains. Roque AC, Lowe CR. Biotechnol Bioeng 91 546-555 (2005)
  74. Oncogenic Hijacking of the PIN1 Signaling Network. Zannini A, Rustighi A, Campaner E, Del Sal G. Front Oncol 9 94 (2019)
  75. Prolyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance. Pu W, Zheng Y, Peng Y. Front Cell Dev Biol 8 168 (2020)
  76. Simplicity is the Ultimate Sophistication-Crosstalk of Post-translational Modifications on the RNA Polymerase II. Venkat Ramani MK, Yang W, Irani S, Zhang Y. J Mol Biol 433 166912 (2021)
  77. Understanding the role of PIN1 in hepatocellular carcinoma. Cheng CW, Leong KW, Tse E. World J Gastroenterol 22 9921-9932 (2016)
  78. A combinatorial view of old and new RNA polymerase II modifications. Lyons DE, McMahon S, Ott M. Transcription 11 66-82 (2020)
  79. Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies. Qin Q, Zhang C, Zhu H, Yang X, Xu L, Liu J, Lu J, Zhan L, Cheng H, Sun X. J Cancer Res Clin Oncol 140 179-188 (2014)
  80. SMURF1, a promoter of tumor cell progression? Xia Q, Li Y, Han D, Dong L. Cancer Gene Ther 28 551-565 (2021)
  81. Do polyproline II helix associations modulate biomolecular condensates? Mompeán M, Oroz J, Laurents DV. FEBS Open Bio 11 2390-2399 (2021)
  82. Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins. Inoue MK, Nakatsu Y, Yamamotoya T, Hasei S, Kanamoto M, Naitou M, Matsunaga Y, Sakoda H, Fujishiro M, Ono H, Kushiyama A, Asano T. Cells 8 E1545 (2019)
  83. Activity and Affinity of Pin1 Variants. Born A, Henen MA, Vögeli B. Molecules 25 E36 (2019)
  84. [Unexpected roles of the peptidyl-prolyl cis/trans isomerase Pin1]. Lavoie SB, Albert AL, Vincent M. Med Sci (Paris) 19 1251-1258 (2003)
  85. Optical chemosensors for the detection of proximally phosphorylated peptides and proteins. Cabral AD, Radu TB, de Araujo ED, Gunning PT. RSC Chem Biol 2 815-829 (2021)
  86. Pin1 Modulation in Physiological Status and Neurodegeneration. Any Contribution to the Pathogenesis of Type 3 Diabetes? Bianchi M, Manco M. Int J Mol Sci 19 E2319 (2018)
  87. [Chromatin and transcription regulation]. Razin SV. Mol Biol (Mosk) 41 387-394 (2007)
  88. Fatal Attraction: The Case of Toxic Soluble Dimers of Truncated PQBP-1 Mutants in X-Linked Intellectual Disability. Chen YW, Rahman SK. Int J Mol Sci 22 2240 (2021)
  89. Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery. Lu KP, Zhou XZ. Sci Signal 17 eadi8743 (2024)
  90. The kingdom of the prolyl-isomerase Pin1: The structural and functional convergence and divergence of Pin1. Lee YM, Teoh DE, Yeung K, Liou YC. Front Cell Dev Biol 10 956071 (2022)
  91. The molecular mechanisms of peptidyl-prolyl cis/trans isomerase Pin1 and its relevance to kidney disease. Wu S, Zou Y, Tan X, Yang S, Chen T, Zhang J, Xu X, Wang F, Li W. Front Pharmacol 15 1373446 (2024)

Articles citing this publication (265)



Quick links